Ivabradine Amarox (Ivabradine Hydrochloride)

Ivabradine blocks the funny (If) current in the sino‑atrial node, which is responsible for spontaneous pacemaker activity. By inhibiting this current, the drug slows the rate of depolarisation, leading to a reduced heart rate while preserving myocardial contractility.

The dose of Ivabradine Amarox is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate targets, and tolerance. Dosage adjustments may be required for renal or hepatic impairment, and the prescriber will provide specific instructions.

Safety data for ivabradine in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Ivabradine Amarox, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting beta‑adrenergic receptors. This makes it useful for patients who cannot tolerate beta‑blockers or need additional rate control beyond what beta‑blockers provide.

Store Ivabradine Amarox at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Ivabradine Amarox is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. Administration timing (e.g., with meals) follows the prescriber’s instructions to maintain consistent plasma concentrations.

Serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and rare visual disturbances such as persistent phosphene phenomena. Patients should be educated to report any episodes of dizziness, fainting, or visual changes promptly.

Ivabradine is contraindicated in patients with severe hepatic impairment, sick sinus syndrome, acute myocardial infarction, unstable angina, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with a resting heart rate below 60 bpm unless specifically directed by a physician.